Cingulate ($CING) Stock Hub: Three Months After the CRL, No Resubmission Date, $28.4 Million of Cash and a Runway Stated Into Mid-2027

01 Latest verified update — September 6, 2026: nothing filed since August 13, and the resubmission still has no date

What was checked. EDGAR shows no filing after the Form 8-K and Form 10-Q of August 13, 2026: no 8-K on a resubmission, no Form 4, no prospectus supplement. No company press release has been issued since the second-quarter report. The Complete Response Letter of June 1, 2026 is therefore three months old with no announced resubmission, classification or action date.

The market at September 4, 2026. Nasdaq close of $5.10, market capitalisation of about $74.2 million on the 14,541,826 shares of the 10-Q cover (Merlintrader calculation). Short interest 10.07% of the float, institutional ownership 12.71%, insiders 17.85%, Finviz aggregate analyst target $21.50. On Stocktwits at September 6, 2026 the normalised sentiment score was 36 out of 100 (bearish label) with 100% of the few tagged messages bullish: opinions of non-professional traders on a thin flow.

What the cash has to cover. The $28.4 million at June 30, 2026 must fund the CMC remediation requested in the CRL, the resubmission, and a commercial build-out that is already running: SG&A doubled to $3.9 million in the quarter while R&D fell 44.9% to $1.5 million. The $5.1 million Avondale note sits entirely in current liabilities because its monthly redemptions are outside the company’s control.

What changes in the reading. Nothing on the regulatory side; on the calendar side, every week without a resubmission moves the earliest possible action date later, because a Class 2 resubmission carries a six-month review clock and a Class 1 a two-month one. The third-quarter report, not yet dated, is the next place the company has to update the resubmission language.

02 Peer-reviewed Phase 3 publication strengthens the clinical record—but does not resolve the FDA manufacturing hold-up

On July 30, Cingulate announced the open-access publication of its pediatric fixed-dose Phase 3 trial in the Journal of Child and Adolescent Psychopharmacology. The paper confirms dose-related ADHD-RS-5 improvement and no new safety signal. It also adds important precision to the company narrative: the 25 mg and 37.5 mg groups met the prespecified multiplicity-adjusted significance threshold, while the 18.75 mg group reported p=0.018 and narrowly missed the required p<0.017 threshold. The authors explicitly describe the findings as preliminary because only 103 of the planned 385 participants were enrolled.

This is a credible scientific positive, not a new regulatory event. It supports the clinical side of the NDA and makes the public evidence base easier to assess, but it does not answer the CMC requests in the June 1 Complete Response Letter. As of September 6, 2026, Cingulate has not publicly confirmed a completed NDA resubmission, FDA classification or new action date. Manufacturing remediation, regulatory timing, cash burn and share issuance therefore remain the variables controlling the equity thesis.

Peer-reviewed pediatric Phase 3: efficacy increased with dose

Placebo-adjusted ADHD-RS-5 treatment difference at Week 5. Longer bars indicate a larger reduction in symptoms versus placebo. Values are taken from the July 2026 paper.

*Critical statistical detail: because three dose comparisons were tested, the prespecified threshold was p<0.017. Therefore, 18.75 mg narrowly missed formal significance despite its nominal p=0.018; 25 mg and 37.5 mg met the threshold. This is more precise than saying that all three doses were statistically significant.

Exploratory effect size

Post hoc placebo-adjusted Cohen’s d for ADHD-RS-5 change. The paper calls the analysis exploratory.

Overall post hoc effect size: 0.901. The result is clinically encouraging, but it cannot restore the statistical power lost when the trial stopped at 103 rather than 385 planned participants.

Treatment-emergent adverse events

Percentage with at least one TEAE during five weeks. All TEAEs were mild or moderate; no serious TEAEs were reported.

Most frequent TEAEs overall: decreased appetite 14.6%, upper abdominal pain 7.8% and headache 6.8%. The highest dose showed the greatest efficacy and the highest TEAE incidence.

Why manufacturing execution is central to the product

CTx-1301’s value proposition depends on three releases occurring reproducibly inside one tablet.

The June CRL is therefore not peripheral “paperwork.” Process controls, dissolution specifications, validation, stability and facility compliance determine whether commercial tablets reproduce the release profile studied clinically.

03 Executive summary

Cingulate is a small, pre-revenue biopharmaceutical company built around a drug-delivery idea rather than a new molecular entity. Its Precision Timed Release, or PTR, platform is intended to place multiple releases of a familiar active ingredient into one tablet. The lead product, CTx-1301, contains dexmethylphenidate, the active ingredient used in established ADHD medicines, but is designed to release it in three pulses: an initial dose for rapid onset, a second delayed dose, and a smaller late-day “built-in booster.” The commercial objective is intuitive. Many patients need symptom control before school or work begins and through the afternoon or evening, yet some existing long-acting products wear off early enough to require an immediate-release booster.

CTx-1301 reached the FDA through the 505(b)(2) pathway, using Focalin XR as the reference listed drug and combining that regulatory bridge with Cingulate’s own pharmacokinetic, food-effect, safety and Phase 3 data. The application was submitted on July 31, 2025, accepted in October, and assigned a May 31, 2026 target action date. The apparent binary did not resolve with approval. On June 2, Cingulate disclosed a Complete Response Letter. According to the company’s SEC filing and press release, the FDA identified specific CMC information requests and did not raise any current clinical safety or efficacy concern.

That wording matters, but it must be interpreted precisely. The actual CRL has not been published. Investors see management’s characterization of the letter, not the complete FDA document. Manufacturing is also not a peripheral issue for this product: the ability to manufacture three releases consistently, at commercial scale, is inseparable from the drug’s value proposition. A CMC-only obstacle may be fixable without another pivotal efficacy trial, but it can still require validation batches, analytical work, stability data, corrective actions at the contract manufacturer, updated documentation or another inspection.

The financing picture is stronger than it was in late 2025 but remains structurally dilutive. The Form 10-Q filed on August 13, 2026 reports $28.4 million of cash and cash equivalents at June 30, 2026 against $11.0 million at December 31, 2025, and $21.6 million of working capital against $1.7 million at year-end. The net loss was $5.9 million for the quarter and $15.2 million for the six months, and operations consumed $12.8 million of cash over the half. Management now describes the cash position as sufficient to fund operations into mid 2027, including the requested CMC work, the effort to secure approval for CTx-1301 and the build-out of support for a commercial launch if the product is approved. That is a narrower statement than the earlier “into 2027” language.

The same filing nonetheless retains an explicit going-concern warning: it states that the uncertainties raise substantial doubt about the ability to continue as a going concern for one year after the issuance date of the financial statements, and Note 1 reaches the same conclusion. A larger cash balance and a retained substantial-doubt conclusion are both in the document, and both belong in the read.

The central investment question is no longer whether CTx-1301 would be approved by May 31. It is whether Cingulate and Bend Bioscience can complete the required manufacturing work, submit a complete response, secure an acceptable FDA classification and reach another action date before cash consumption and dilution overwhelm the remaining product value. The Q2 filing puts a price on the first step for the first time: approximately $1.6 million of Bend Bioscience agreements covering the CMC work supporting resubmission, including manufacture of verification batches, plus approximately $7.0 million for the manufacture of process validation batches. Roughly $8.6 million of contracted manufacturing work therefore sits between the company and a resubmission-ready file.

The July 2026 peer-reviewed publication strengthens the clinical evidence base but does not change that hierarchy. The journal paper confirms meaningful dose-related symptom improvement, yet it also clarifies the limits of the study: only two of three doses crossed the prespecified multiplicity-adjusted threshold, the effect-size analysis was post hoc, the trial enrolled 103 of 385 planned participants, and time-of-day efficacy was not directly measured in this fixed-dose study. The authors’ own conclusion is appropriately cautious and calls the findings preliminary pending confirmation in a larger, adequately powered study.

The one-sentence thesis

CING is a clinically supported but manufacturing-blocked ADHD special situation in which the next durable re-rating requires regulatory proof—resubmission, classification and a new action date—not another promotional description of the product.

04 Catalyst map

05 Company history: from a delivery-platform concept to a public-company FDA setback

Cingulate Therapeutics was formed in November 2012. The public holding company was created in 2021, acquired the operating business through a reorganization merger, and completed its initial public offering in December of that year. The founding concept was not to discover an entirely new stimulant. It was to improve how established ADHD drugs are delivered across a patient’s active day.

The company licensed controlled-release barrier-layer technology from BDD Pharma. Under that agreement, Cingulate obtained exclusive rights within defined fields to develop products capable of delivering three distinct doses of dexmethylphenidate, dextroamphetamine or related stimulant compounds. The economic obligation is not trivial but is manageable relative to a successful branded product: the 2025 Form 10-K described a final $250,000 milestone upon FDA approval of CTx-1301 and low- to mid-single-digit royalties on applicable net sales or receipts.

Cingulate’s corporate life has repeatedly alternated between scientific progress and financing stress. The company has never generated product revenue. It used private capital before the IPO, public offerings, at-the-market sales, equity purchase facilities, debt, warrant inducements and private placements to fund development. It also completed a 1-for-20 reverse stock split in November 2023 and a 1-for-12 reverse split in August 2024. Those actions preserved the Nasdaq listing but are essential context when looking at long-term price charts: historical per-share prices are mechanically inflated by cumulative split adjustments and do not represent comparable economic value.

By 2025, the company had moved beyond early pharmacokinetic proof and into a filing campaign. Safety updates, a pre-NDA meeting, a high-dose food-effect study and pediatric efficacy data were followed by an FDA user-fee waiver and the July 31 NDA submission. Cingulate simultaneously built the commercial and manufacturing infrastructure it believed it would need after approval. This included an exclusive manufacturing relationship with Bend Bioscience, commercial services with Indegene and an arrangement with IQVIA for field sales and national account management.

The same manufacturing strategy that signaled launch readiness became the central regulatory weakness. In February 2026, the FDA conducted a pre-approval inspection of Bend’s Gainesville, Georgia facility. The CDMO received a Form 483 with three observations: two related to the facility and one specific to CTx-1301. Cingulate had already disclosed multiple FDA information requests, primarily related to CMC. The CRL therefore did not emerge from nowhere. It crystallized a risk visible in the company’s own March filing.

06 Full timeline

07 How PTR and CTx-1301 are designed to work

CTx-1301 is a film-coated, multi-core tablet containing dexmethylphenidate hydrochloride. The company expects eight dosage strengths ranging from 6.25 mg to 50 mg. Its differentiation is the release architecture. The tablet combines an immediate-release component with two delayed-release cores surrounded by erosion barrier layers. Those barriers are engineered to prevent premature release and then erode at predefined times.

The intended dexmethylphenidate release ratio is 35% initially, 45% in the second pulse and 20% in the third pulse. The late 20% pulse is the “built-in booster.” Rather than asking a patient to carry and take a separate short-acting stimulant later in the day, Cingulate wants one morning tablet to supply an early effect, reinforce exposure as the first dose declines and extend useful coverage into the late active day. The company also argues that a controlled descent in plasma levels may reduce the abrupt wear-off, rebound or crash some patients experience.

This is a credible product-design hypothesis, but it creates a high manufacturing bar. Each layer, core, dissolution profile and dose strength must be produced consistently. The regulatory question is not simply whether dexmethylphenidate works—it is already a well-known stimulant—but whether this precise product can be manufactured reproducibly, remain stable, meet specifications and deliver the intended profile across commercial batches.

The platform itself is partly dependent on licensed BDD Pharma technology, including the Oralogik erosion barrier formulation. Cingulate owns and is building additional intellectual property around its specific products and release profiles. The June 2026 U.S. patent is therefore valuable: it protects key aspects of the CTx-1301 formulation and method of use through December 2042. Still, a patent protects exclusivity; it does not validate manufacturing readiness, FDA approvability, reimbursement or market adoption.

08 Clinical evidence: what the data show and what they do not

Phase 1/2 bridge to Focalin XR

In the 2020 comparative bioavailability study, Cingulate reported that adjusted geometric mean ratios for the primary exposure parameters were within the conventional 80%–125% range versus Focalin XR at tested high and low doses. That work created the scientific bridge to the reference listed drug. A later analysis also suggested that the three-pulse profile delivered the planned late-day exposure and that study-drug-related treatment-emergent adverse events were lower than with Focalin XR in that small program.

For a 505(b)(2) product, this bridge matters because the sponsor can rely in part on the FDA’s prior findings for the referenced drug while supplying data needed to support the formulation differences. It is not the same as filing a simple generic application. CTx-1301’s release pattern and proposed clinical use must still be adequately supported.

Adult Phase 3: encouraging effect sizes, but a missed primary endpoint

The adult laboratory-classroom study enrolled only 21 adults aged 18–55. Following dose optimization, participants were randomized to CTx-1301 or placebo. The primary PERMP comparison over the 16-hour assessment showed a trend toward statistical significance, with p=0.089, but did not meet the standard threshold. This is the most important limitation in the adult efficacy story and should never be hidden behind the company’s effect-size language.

The supportive results were better. Cingulate reported PERMP effect sizes ranging from 0.88 to 2.60, averaging 1.79; the treatment effect was 1.41 at 30 minutes and 0.98 at 16 hours. CGI-S improved by 1.2 points in the active arm versus no change on placebo, with p<0.001, and AISRS scores fell by 16.3 points. Only one mild treatment-emergent adverse event was reported in the active arm during the randomized period, versus three events in the placebo group.

The balanced interpretation is straightforward: the small adult study did not establish the primary endpoint statistically, but the temporal effect-size pattern and secondary measures were sufficiently supportive for the FDA to accept an application that also relied on the 505(b)(2) bridge and the broader clinical package. The CRL, as summarized by Cingulate, did not reopen the efficacy question. That does not convert an underpowered primary-endpoint miss into a success; it means the disclosed approval obstacle is elsewhere.

Pediatric Phase 3: peer review confirms dose response—and exposes the limits of the headline

The pediatric fixed-dose study enrolled 103 patients aged 6–17, versus an original plan for 385, after the FDA advised that further conduct of the pediatric studies was not required for the NDA. The July 2026 peer-reviewed paper reports mean ADHD-RS-5 reductions of 18.0, 17.8 and 22.0 points for the 18.75-mg, 25-mg and 37.5-mg groups, respectively, compared with an 8.1-point reduction on placebo. The model-based placebo-adjusted treatment differences were −8.81, −9.34 and −14.16 points.

The statistical interpretation requires precision. Cingulate’s July 30 release listed nominal p-values of 0.018, 0.011 and 0.001 and said all three dose groups improved versus placebo. However, the protocol used a stricter two-sided threshold of p<0.017 to account for the three comparisons. Under that prespecified rule, the 25-mg and 37.5-mg groups were statistically significant; the 18.75-mg group narrowly missed. The paper’s abstract and discussion state that statistical significance was not consistent across all doses.

The exploratory post hoc Cohen’s d effect sizes were 0.732, 0.782 and 1.185, with an overall effect size of 0.901. CGI-S improvement crossed the adjusted significance threshold only at 37.5 mg. Among the 83 participants with Week 5 CGI-I data, 57.1%, 57.1% and 68.4% in the active-dose groups were rated “much improved” or “very much improved,” versus 18.1% on placebo. A pooled post hoc analysis across all active doses was nominally significant, but pooled and post hoc results should not be confused with prespecified individual-dose testing.

The clinical signal is meaningful, especially given the small treatment groups, but the authors call the findings preliminary and say confirmation in a larger, adequately powered study is needed. They also note that common psychiatric comorbidities were excluded and that this trial did not measure time-of-day-specific efficacy; therefore, the company’s intended “entire active day” benefit cannot be directly inferred from this study alone.

Peer-reviewed safety details

During the five-week treatment period, at least one treatment-emergent adverse event was reported in 38.5% of placebo recipients, 50.0% of the 18.75-mg group, 34.6% of the 25-mg group and 68.0% of the 37.5-mg group. All TEAEs were mild or moderate. No serious TEAE or new safety signal was identified. The most frequently reported events across the study were decreased appetite at 14.6%, upper abdominal pain at 7.8% and headache at 6.8%.

Three participants discontinued treatment because of a TEAE: one placebo participant with joint stiffness, one 18.75-mg participant with headache and one 37.5-mg participant with chest pain. Each event was moderate, considered at least possibly treatment-related and resolved during follow-up. The highest dose therefore carried both the strongest efficacy signal and the highest TEAE incidence, reinforcing the practical importance of dose optimization if the product is approved.

Safety and food effect

Cingulate combined adult and pediatric safety information with food-effect work at the 25-mg and 50-mg strengths. The company reported no serious treatment-emergent adverse event, no TEAE leading to death and no clinically relevant overall TEAE trend in the analyzed studies. Both tested strengths supported dosing with or without food.

CTx-1301 remains a stimulant containing a Schedule II controlled substance. If approved, labeling would be expected to reflect class risks, including abuse, misuse, dependence and cardiovascular or psychiatric warnings where applicable. A favorable development-program safety summary does not make the product free of the established risks of dexmethylphenidate.

09 The CRL: what is known, what is missing and why CMC can take time

Confirmed facts

• The FDA issued a Complete Response Letter for the CTx-1301 NDA.
• Cingulate’s June 2 SEC filing says the letter identified specific CMC information requests.
• The company said no current clinical safety or efficacy concerns were raised.
• The full CRL has not been released publicly.
• A February 2026 pre-approval inspection of the contract manufacturer resulted in three Form 483 observations, including one specific to CTx-1301.
• As of September 6, 2026, no completed resubmission, FDA classification or new action date has been announced.

CMC covers the chemistry of the drug and excipients, the manufacturing process, analytical methods, specifications, stability, controls, facilities and evidence that commercial production can repeatedly make the product described in the application. For a simple tablet, this is already demanding. For a tablet whose purpose depends on three precisely timed releases, the relationship between process control and clinical behavior is even more direct.

A Form 483 is not itself a final agency determination that a company violated the law, and a CRL is not a permanent rejection. But both are serious. The FDA generally cannot approve a drug if it is not satisfied that manufacturing processes and facilities comply with current good manufacturing practice and can produce a consistent product. Cingulate must therefore close both the documentary and operational gap, not merely argue that the clinical data are good.

Possible workstreams include corrective and preventive actions at the facility, analytical-method validation, dissolution or release-specification work, process-performance qualification, updated batch records, stability packages and responses connecting any process change back to the submitted product. These are examples of what CMC remediation can involve, not a claim that every item appears in Cingulate’s confidential letter.

Class 1 versus Class 2

After a CRL, the FDA classifies a complete resubmission based on the scope of the response. A Class 1 response is generally associated with a two-month review goal; a Class 2 response is generally associated with a six-month goal. The clock begins after the agency receives and accepts a complete resubmission, not when management says work is progressing.

It is premature to assume Cingulate will receive Class 1 treatment. CMC responses that include substantial new data, validation or inspection work can support a Class 2 classification. Until the company submits and the FDA classifies the response, both timing paths remain scenarios rather than facts.

The 2027 option-award clue—useful, but not guidance

On July 20, Cingulate filed Form 4 reports for option awards granted on July 16. For CEO Shane Schaffer, 97,350 of the 295,000 options were structured so that vested options become exercisable only if the FDA approves CTx-1301 during 2027; the conditional portion terminates if approval does not occur during that year. Similar approval-contingent tranches were disclosed for other executives.

This design aligns some compensation with the regulatory outcome and indicates that a 2027 approval is important in the board’s incentive framework. It is not a promise that the resubmission will occur on a particular date, not confirmation of Class 1 or Class 2 status, and not evidence that the FDA has agreed to approval in 2027.

10 Manufacturing and launch infrastructure

Cingulate does not own a commercial manufacturing facility. CoreRx, doing business as Bend Bioscience, is contracted to manufacture clinical, registration and—if approved—commercial CTx-1301 batches at its Gainesville, Georgia facility. Cingulate supplied equipment for a dedicated suite. The commercial supply agreement runs through August 2028, subject to its terms and possible renewal.

This outsourced model can limit fixed infrastructure costs, but it concentrates execution risk. If Bend’s facility, quality systems or product-specific process are not acceptable to the FDA, Cingulate cannot launch simply by having an approved clinical package. Moving to another manufacturer would not be a quick workaround; technology transfer, validation and regulatory amendments could add substantial time and expense.

Commercially, the company intends to avoid building a large standalone organization. Indegene can provide medical affairs, pricing, reimbursement, market access, operations and marketing under statements of work. IQVIA can support field sales and national accounts. Bryan Downey, appointed Chief Commercial Officer in November 2025, adds internal launch leadership.

That asset-light commercial plan is rational for a small company, but it does not eliminate launch costs or risk. Cingulate must fund inventory, distribution, rebates, payer contracting, medical education and sales execution before product cash flow can finance the operation. Every month of regulatory delay forces a choice between preserving readiness and conserving cash.

11 Market opportunity and competition

ADHD is a large, established market with tens of millions of diagnosed U.S. patients and approximately 100 million annual prescriptions according to Cingulate’s June release. Stimulants remain the most effective pharmacologic class for many patients. The opportunity is not based on creating a treatment category from nothing; it is based on persuading prescribers, payers and patients that a differentiated duration profile is worth using and reimbursing.

CTx-1301 would compete with generic immediate- and extended-release methylphenidate products, Focalin XR and generics, Concerta and generics, amphetamine products such as Adderall XR and Vyvanse, and newer branded formulations designed around onset, duration, convenience or abuse-deterrence. Generic availability creates price pressure. A novel delivery profile can earn a branded position, but payer access will depend on evidence, rebates and step-edit policies.

The product’s best commercial argument is practical: one morning tablet could replace an extended-release product plus an afternoon booster, simplify adherence and reduce the need to handle short-acting controlled medication at school or work. The hardest question is whether real-world patients and prescribers experience enough additional useful duration, with acceptable sleep, appetite and tolerability, to overcome formulary friction.

Aytu BioPharma remains a useful but imperfect peer. Aytu demonstrates that a small specialty-pharma company can operate an ADHD portfolio and generate meaningful revenue. It does not prove Cingulate’s launch economics. Aytu entered the comparison with commercial products and infrastructure; Cingulate is still pre-revenue and must cross manufacturing, approval, launch and financing hurdles in sequence.

12 Pipeline beyond CTx-1301

CTx-1302 uses the same platform logic with dextroamphetamine: 45% immediate release, 35% approximately three hours later and a 20% built-in booster around seven hours. The proposed program includes comparative bioavailability, food-effect and Phase 3 studies, but the company has clearly stated that initiation depends on funding.

CTx-2103 applies PTR to buspirone, an anxiety medicine commonly taken multiple times per day. A 10-subject formulation study tested delayed and triple-pulse tablets and produced pharmacokinetic and imaging information. The idea is commercially interesting because buspirone is non-benzodiazepine and widely used, but it remains far behind CTx-1301. Investors should not assign mature-product value to programs the company cannot advance without new capital.

13 Financial condition: stronger cash, still no self-funding business

The balance-sheet improvement came from financing, not operations. Six-month financing cash flow was $30.4 million while operations consumed $12.8 million, moving cash from $11.0 million at the start of the year to $28.4 million at June 30, 2026. Cingulate remains pre-revenue and cannot fund itself until an approved product is launched, reimbursed and sold at sufficient scale.

The forward read has narrowed to two questions. The first is whether SG&A, which doubled year over year while research spending fell 44.9%, is rephased now that the CRL has pushed a launch out. The second is how the roughly $8.6 million of contracted Bend Bioscience manufacturing work is funded, because it is committed spending that sits ahead of a resubmission the company has not dated. Both sit next to the going-concern language, which the filing retained even with $28.4 million of cash on the balance sheet.

14 Capital structure and dilution risk

The share count has roughly doubled in a little over seven months. Cingulate had 7,250,299 common shares outstanding at December 31, 2025, 11,908,316 at March 31, 2026 and 13,894,882 at June 30, 2026. The cover of the Q2 Form 10-Q reports 14,541,826 shares outstanding as of August 12, 2026, an increase of 100.6% against the year-end figure. The 13,469,036 shares reported in the May 2026 proxy statement as of May 18, 2026 are a historical waypoint in that sequence, not the current count, and none of these figures include potential future issuance from warrants, options and financing facilities.

Two facilities did most of the work in the quarter. Under the A.G.P. at-the-market programme entered into on March 24, 2026, with capacity of up to $100,000,000 gross and a 3% commission, Cingulate sold 806,893 shares during the second quarter for net proceeds of $4,347,364 after $136,364 of A.G.P. compensation and administrative fees; the six-month totals were 809,593 shares for $4,364,909 net. Under the Lincoln Park purchase agreement of July 21, 2025, which allows up to $25.0 million over a 36-month term, the company sold 1,032,372 shares in the quarter for net proceeds of $5,058,975, and 2,644,178 shares across the six months for $14,065,761 net. The earlier H.C. Wainwright 2023 at-the-market programme, for up to $31.9 million, was terminated effective March 23, 2026 after 210,158 shares had been sold in the six months for net proceeds of $1,304,011. The company’s Q2 release aggregates the at-the-market and Lincoln Park activity as approximately $19.0 million of capital raised in the first half, against $12.8 million of cash used for operations. The 10-Q does not disclose how much capacity remains under either the A.G.P. programme or the Lincoln Park agreement, so the remaining headroom cannot be read from the filing.

The February 2026 private placement included 2,147,472 common shares, 954 Series A convertible preferred shares with a $1,000 stated value and a 12% dividend that auto-converted into 191,824 common shares on March 24, 2026 at $5.04, and warrants for 1,869,415 shares at a $5.04 exercise price, for gross proceeds of approximately $12.0 million. Those warrants are the live overhang. Total warrants outstanding at June 30, 2026 were 2,620,963, of which the 1,869,415 February tranche is by far the largest, and none of them had been exercised through June 30, 2026. The remaining tranches are small: 354,167 June 2024 Series C and 177,083 June 2024 Series D warrants at $7.02, 135,417 February 2024 public-offering warrants at $24.00, 21,250 July 2024 placement-agent warrants at $8.78 and 28,855 September 2023 Series A warrants at $13.56, plus legacy 2021 and 2023 tranches struck at $1,440.00, $1,800.00, $172.80 and $30.00 that are far out of the money. Potentially dilutive securities excluded from the earnings-per-share calculation, covering stock options and common stock purchase warrants, totalled 3,784,266 at June 30, 2026 against 1,232,523 a year earlier. The placement’s 180-day lock-up and its 24-month standstill capped at 40% as converted reduced immediate supply from those investors; they did not remove the shares or warrants from the capital structure.

Issuance did not stop at the quarter end. After June 30, Cingulate sold 220,476 further shares to Lincoln Park for net proceeds of $1,068,525 and 271,717 shares under the A.G.P. programme for net proceeds of $1,394,179 after $43,751 of A.G.P. compensation, roughly $2.46 million of net equity proceeds against $600,000 of cash paid to Avondale. It also issued 139,751 shares to Avondale in exchange for $1,320,000 of note principal, and issued 67,924 shares on July 7, 2026 at $5.30 and 71,827 shares on August 10, 2026 at $5.01 in Section 3(a)(9) debt-for-equity transactions. On July 9, 2026 stockholders approved an equity incentive plan amendment increasing the authorised shares by 625,000; 458,888 plan shares remained available at June 30, 2026, and the plan carries an automatic January 1 evergreen equal to 5% of fully diluted shares outstanding at the preceding December 31. The subsequent S-8 registered 1,139,300 additional shares, including the new plan shares, the 2026 evergreen increase and earlier inducement awards. Registration does not mean all shares were issued immediately, but it does mean compensation-related issuance belongs in any fully diluted analysis.

Dilution bottom line

Cash runway and dilution are two sides of the same equation, and the second quarter moved both at once: cash rose to $28.4 million while the share count rose to 14,541,826 on the August 12, 2026 cover, roughly double the December 31, 2025 level. A stronger share price and a dated resubmission could let Cingulate finance on better terms; a long delay or weak market could require more shares for each dollar raised, with 2,620,963 warrants outstanding and 3,784,266 potentially dilutive securities already excluded from the loss-per-share calculation. The correct question is not only “does the company have cash?” but “how much per-share value remains after the capital needed to reach approval and launch?”

15 Ownership, insiders and governance

Falcon Creek Capital Advisor was the only holder above 5% listed in the May proxy, with 3,856,766 shares beneficially owned, or 25.91% under the filing’s calculation. The position includes securities purchased through the February private placement on behalf of managed funds. Falcon Creek also received board-designation rights tied to ownership thresholds. This creates a more concentrated strategic shareholder than Cingulate had before the financing, but it also gives one capital provider meaningful influence.

Directors and executive officers as a group beneficially owned 739,628 shares, or 5.30%, using the proxy’s SEC methodology and including certain exercisable options or warrants. Several officers, directors and affiliates participated in the February financing. That is a constructive alignment signal, although insider participation does not eliminate regulatory or dilution risk. Both the 25.91% and the 5.30% figures come from the May 2026 proxy and have been diluted by subsequent issuance, since shares outstanding have risen from 13,469,036 on May 18, 2026 to 14,541,826 on August 12, 2026.

Governance requires a more cautious reading. Shane Schaffer’s 2025 administrative leave and later reinstatement were disruptive at a sensitive stage. In July 2026, the board was reduced to five directors, Schaffer became chairman, Jeff Hargroves became lead independent director, and committee leadership was reorganized. Investors should monitor whether the smaller board maintains sufficient independent challenge while the company manages a high-stakes regulatory and financing process.

The July option awards included both time-based and FDA-approval-contingent components. Performance alignment is positive in principle. The size of the equity plan and recurring share grants still carry a per-share cost. Both statements can be true.

16 Analyst and research coverage

Cingulate’s official investor-relations materials identify outside coverage, while public aggregators show several bullish ratings and widely dispersed targets. The most recent clearly reported post-CRL target in public databases is Ascendiant Capital’s $52 target dated June 8, 2026. Roth Capital had a $16 target in November 2025, before the CRL. Other aggregators produce averages around the low-to-high $20s, but their constituent dates and inclusion rules differ.

Those numbers should be treated as analyst opinions, not valuation anchors. A pre-revenue micro-cap with a confidential CRL, uncertain resubmission class and variable future share count can produce enormous differences between models. Stonegate’s June research update does not issue a formal rating or price target and shifted expected revenue to the second half of 2027. Its timing assumption is also not company guidance.

The useful takeaway from coverage is not the headline upside percentage. It is the set of model variables: approval timing, probability of success, launch date, peak penetration, gross-to-net deductions, commercial cost, cash needs and diluted share count. Any target that does not remain updated for the CRL and new issuance is stale.

17 Retail sentiment and trading behavior

CING attracts retail attention because it combines a small market capitalization, a recognizable FDA narrative, a large-addressable-market story and a relatively low nominal share price. The result is headline sensitivity. “No safety or efficacy concerns” supports a fast-fix narrative; “FDA rejection” and “manufacturing issue” support the opposite narrative. Both can drive sharp moves before new evidence appears.

Social-media discussion on Stocktwits, Reddit and X should be treated as sentiment, not due diligence. Retail commentary can reveal which catalyst is being priced and where expectations are crowded. It cannot verify the content of a confidential CRL, the status of validation work or the FDA’s future classification. Volume, borrow conditions and float concentration can amplify reactions in either direction.

18 Scenario framework

Bull case

The CMC requests are specific and addressable. Bend completes corrective work and validation without a long additional stability requirement or disruptive reinspection. Cingulate resubmits during 2026, the FDA accepts the response on a manageable timetable, and approval occurs during 2027. Cash is sufficient to reach the decision with limited incremental dilution, while Indegene and IQVIA allow a focused launch. The patent estate supports a durable branded opportunity.

Base case

The product remains approvable, but remediation and documentation take longer than early company language suggested. The resubmission receives a Class 2 review or otherwise pushes the new action date into 2027. Cingulate slows some commercial activity but still uses the ATM or Lincoln Park facility. Approval probability survives, while per-share value is moderated by time, burn and new issuance.

Bear case

The CMC deficiencies require extensive batch, stability, process or facility work. A new inspection or incomplete response adds delay, the cash runway compresses, and financing occurs at unfavorable prices. The company may be forced to reduce programs, seek a partner from a weak negotiating position or issue substantial equity. Even eventual approval could arrive after material dilution and with launch resources constrained.

19 Red flags

• The NDA was not approved. “No current clinical concern” does not erase the CRL.
• The full letter is confidential. Public analysis depends on the company’s summary.
• Manufacturing is the product. A precision-release medicine cannot separate its clinical promise from process reproducibility.
• No resubmission date is confirmed. Management videos and patent news are not regulatory milestones.
• The adult primary endpoint missed statistical significance. Supportive secondary and effect-size data do not change that fact.
• The pediatric study ended early. It produced positive data, but with 103 participants rather than the planned 385.
• Cingulate has no product revenue. It remains dependent on external capital.
• Dilution capacity is large. ATM, Lincoln Park, warrants, options and plan shares can all expand the denominator.
• Commercial spending began before approval. Preserving readiness during a long delay can consume cash rapidly.
• Governance has a history of disruption. The 2025 CEO leave and 2026 board changes warrant continued attention.
• Competition is established and often generic. Clinical differentiation must translate into payer access and prescribing behavior.
• Controlled-substance regulation adds complexity. DEA quotas, security, distribution and class labeling matter after approval.
• Going-concern doubt is retained. The Q2 10-Q still states that the uncertainties raise substantial doubt about the ability to continue as a going concern for one year after the issuance date of the financial statements, even with $28.4 million of cash at June 30, 2026.
• The remediation now has a price tag. Roughly $8.6 million of contracted Bend Bioscience work, about $1.6 million for the CMC package including verification batches and about $7.0 million for process validation batches, is committed ahead of any resubmission.
• The share count has roughly doubled since December 31, 2025. Shares outstanding rose from 7,250,299 at year-end to 14,541,826 on the August 12, 2026 cover, and equity sales continued after the quarter closed.
• The whole Avondale note is now a current liability. Avondale may redeem up to $660,000 per month from May 7, 2026, which is outside the company’s control, and the June CRL extinguished the note’s redemption-deferral right because that right applied only while no complete response letter had been received.

20 What would change the thesis?

Evidence that would improve the setup

• A precise resubmission date accompanied by completed CMC work rather than a broad intention.
• FDA acceptance and a clearly disclosed Class 1 or otherwise short review timetable.
• Confirmation that facility and product-specific observations are closed or do not require further inspection.
• Post-CRL spending discipline that preserves cash without dismantling launch capability.
• A strategic partnership that contributes capital or commercial infrastructure on credible terms.

Evidence that would weaken the setup

• A resubmission delay without technical explanation.
• New validation, stability or inspection requirements extending beyond current expectations.
• Rapid ATM use at depressed prices or a deeply discounted financing.
• A new FDA concern involving clinical data, labeling or abuse potential.
• Management turnover, manufacturer disruption or a need to transfer production.

21 Merlintrader bottom line

Cingulate correctly identified a real treatment inconvenience: one morning stimulant does not always cover a full modern school, work and family day, and a separate booster creates adherence, handling and diversion problems. CTx-1301’s three-pulse design is a rational response. The clinical package is not flawless—the small adult trial missed its primary statistical threshold and the pediatric study stopped early—but it contains meaningful supportive evidence, and the disclosed CRL did not identify a current safety or efficacy defect.

The mistake would be to conclude that a CMC letter is merely paperwork. The FDA’s manufacturing standard exists to ensure that the tablet patients receive consistently behaves like the tablet studied. That is especially important when timed release is the product’s central advantage. Until Cingulate proves the remediation path through a complete resubmission and FDA classification, the company remains in regulatory limbo.

The cash position gives Cingulate a chance to solve the problem. It does not grant unlimited time. The Q2 filing shows $28.4 million of cash and $21.6 million of working capital at June 30, 2026 against $12.8 million consumed by operations over six months, and management now describes the runway as into mid 2027 rather than into 2027. The same filing keeps an explicit substantial-doubt conclusion on going-concern status, and it discloses roughly $8.6 million of contracted Bend Bioscience manufacturing work committed ahead of a resubmission that still has no date. Meanwhile the share count reached 14,541,826 on the August 12, 2026 cover, roughly double the December 31, 2025 level. Enterprise progress and per-share outcomes can therefore diverge: CTx-1301 can move closer to approval while existing holders are still diluted.

For catalyst-focused readers, the hierarchy is clear: first the CMC work, then the resubmission, then the FDA classification, then the new action date, then approval and finally launch execution. Everything else—including patents, index inclusion, interviews, option incentives and analyst targets—is secondary until that sequence resumes.

22 Frequently asked questions

No. The FDA completed the original review cycle with a Complete Response Letter. CTx-1301 cannot be marketed unless Cingulate addresses the deficiencies and later receives an approval letter.

Not according to Cingulate’s June 2 SEC filing and press release. The company said the identified requests were CMC-related and no current clinical safety or efficacy concern was raised. The full CRL is not public, so this remains the company’s disclosed characterization.

No exact public resubmission date was confirmed as of September 6, 2026. The Form 10-Q filed that day says Cingulate intends to resubmit as promptly as practicable and adds that there can be no assurance regarding the timing of any resubmission, that any resubmission will be accepted by the FDA, or that approval will occur at all. Investors should wait for a formal announcement that the complete response has been filed.

It independently reviewed and publicly detailed the 103-patient pediatric fixed-dose study. The 25-mg and 37.5-mg groups met the prespecified p<0.017 threshold for the primary ADHD-RS-5 endpoint; the 18.75-mg group narrowly missed at p=0.018. No serious TEAEs or new safety signals were reported. Because the trial enrolled 103 of 385 planned participants, the authors described the findings as preliminary and said larger confirmation is needed.

Yes, it is a plausible scenario, and July option awards include approval-in-2027 conditions. It is not guaranteed. Timing depends on completion of the CMC work, the filing date, FDA classification, inspection needs and the absence of new deficiencies.

It determines the expected length of the FDA review after a complete resubmission. A shorter Class 1 goal would reduce time and cash burn; a Class 2 review generally means a longer six-month goal and greater financing exposure.

No. Patent protection can preserve exclusivity and improve future product economics, but it does not establish safety, efficacy, manufacturing compliance or permission to market the drug.

23 Related Merlintrader coverage

• Cingulate: first full deep dive into the original May 31, 2026 FDA binary
• Cingulate vs. Aytu BioPharma: what a commercial ADHD peer can and cannot tell us
• Cingulate Q1 2026: cash build and commercial readiness before the FDA decision
• Cingulate’s CTx-1301 CRL: what went wrong and what comes next

The block below is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.

24 Position disclosure

Merlintrader / the author previously held a small position in Cingulate. The position was sold on June 29, 2026 at $5.21 for a small gain. The author did not hold a CING position at the time of this September 6, 2026 update. This disclosure is provided for transparency and does not constitute a recommendation to buy, sell or hold the security.